Linzagolix + add-back therapy offers sustained symptom control in endometriosis :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Linzagolix + add-back therapy for endometriosis pain: Findings from EDELWEISS 6 trial

Endometriosis Endometriosis
Endometriosis Endometriosis

Endometriosis, a chronic estrogen-dependent inflammatory ailment, triggers severe pelvic pain and dysmenorrhea. 

See All

Key take away

Long-term administration of once-daily oral linzagolix, particularly at a 200 mg dose combined with hormonal add-back therapy, sustains high pain response rates and quality-of-life improvements in women with endometriosis over 12 months.

Background

Endometriosis, a chronic estrogen-dependent inflammatory ailment, triggers severe pelvic pain and dysmenorrhea. While the 24-week pivotal EDELWEISS 3 trial established the short-term potency of linzagolix—an oral Gonadotropin-Releasing Hormone (GnRH) antagonist—the EDELWEISS 6 study explored whether efficacy, safety, bone mineral density (BMD) protection, and tolerability are sustained through 12 months of active treatment and a subsequent 6-month off-treatment follow-up.

Method

EDELWEISS 6 was a prospective, randomized, double-blind extension and withdrawal study. A total of 353 premenopausal women with moderate-to-severe endometriosis who successfully completed the 6-month EDELWEISS 3 trial were recruited. Volunteers received either 75 mg linzagolix alone or 200 mg linzagolix combined with hormonal add-back therapy (ABT) once daily from month 6 to month 12, followed by a 6-month post-treatment follow-up.

Co-primary endpoints focused on the reduction of dysmenorrhea and non-menstrual pelvic pain at month 12, alongside assessments for dyschezia (difficulty in defecating), dyspareunia (painful intercourse), quality of life (checked via the Endometriosis Health Profile-30 [EHP-30] questionnaire), analgesic use, body mass index (BMI), and adverse events (such as vasomotor symptoms).

Result

At month 12, therapeutic efficacy was robustly maintained. Both linzagolix regimens improved dysmenorrhoea and non-menstrual pelvic pain, with higher response rates for dysmenorrhoea in the 200 mg linzagolix + ABT group (Table 1):

Both dosing regimens yielded steady reductions in daily dyschezia, dyspareunia, and overall pelvic pain scores, with superior outcomes observed in the 200 mg + ABT cohort. EHP-30 total scores illustrated clear improvements across all five dimensions. Safety outcomes remained favorable: BMI changes were minimal, adverse events such as hot flushes occurred in fewer than 1% of participants, and risks of BMD loss were successfully mitigated by concomitant ABT. Partial symptom relief persisted for several months during the subsequent 6-month off-treatment follow-up period.

Conclusion

Oral linzagolix (200 mg once daily with hormonal ABT) represents an effective, safe, and durable long-term medical therapy for endometriosis-linked pain, reducing analgesic reliance and substantially boosting health-related quality of life. Additionally, the 75 mg monotherapy regimen provides a valuable alternative for long-term care in those who require or prefer treatment without concomitant hormonal ABT.

Source:

Human Reproduction Open

Article:

Linzagolix, with and without add-back therapy, in women with endometriosis-associated pain: results from EDELWEISS 6, a double-blind randomized extension and withdrawal study

Authors:

Jacques Donnez et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: